LS Bio

LSBio’s catalog includes 530,000 monoclonal and polyclonal antibodies to 19,000 targets. Antibodies are available for most species and all major research applications, such as IHC, IF, WB and FACS. Through extensive ongoing in-house testing, more than 15,000 of these antibodies have also been identified as exceptional IHC reagents and given the IHC-plus™ brand.

LSBio also offers 54,000 high quality immunoassays, including sandwich ELISA (enzyme-linked immunosorbent assay) kits and competitive EIA (enzyme immunoassay) kits, as well as cell-based and DNA-binding kits.

LSBio additionally offers 98,000 native protein extracts and engineered recombinant proteins in the form of cell lysates or highly purified reagents.

Major product lines from LS Bio

• ELISA kits
• IHC-plus™ immunohistochemistry antibodies
• PathPlus™ immunohistochemistry antibodies
• Isotype controls
• Proteins
• Primary antibodies
• Secondary antibodies

LSBio is a part of Absolute Biotech, who also has a number of other brands such as: Absolute Antibody, Nordic-MUBio, Kerafast and Everest Biotech. Bio-Connect Life Sciences supplies all brands in the Benelux. If you have any questions, please contact the helpdesk.

IHC-plus™ Immunohistochemistry Antibodies

LSBio is a leading supplier of immunohistochemistry (IHC) antibodies. Our 15,000 IHC-Plus™ antibodies have been rigorously tested to deliver optimal performance in IHC studies on formalin-fixed paraffin-embedded (FFPE) human tissues. View all here.

PathPlus™ Immunohistochemistry Antibodies

These antibodies represent the highest quality reagents available for research pathology applications. Over 2,000 antibodies were hand-selected from among thousands that were tested and identified to be the best performing reagents for immunohistochemical detection of high-value cancer and neuroscience targets in formalin-fixed paraffin-embedded human tissues. View all here.

Research Area Focuses

LSBio has focused much of its efforts on developing and testing reagents for use in the fields of oncology, neurological disorders and virology. Highly validated IHC antibodies are available to key targets associated with breast, colon, lung and prostate cancer, as well as Alzheimer’s disease.